Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Michael Kreuter(Johannes Gutenberg University Mainz), Toby M. Maher(University of Southern California), Derek Weycker(Policy Analysis (United States)), Argyrios Tzouvelekis(University of Patras), Mark Atwood(Policy Analysis (United States)), Philip L. Molyneaux(Guy's and St Thomas' NHS Foundation Trust), Joyce Lee(Inserm), Klaus-Uwe Kirchgaessler(Roche (Switzerland)), Justin M. Oldham(Michigan Medicine)
American Journal of Respiratory and Critical Care Medicine
January 12, 2021
Cited by 198
Related Papers
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k
Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important Difference
|American Journal of Respiratory and Critical Care Medicine|2011|523
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Pulmonary fibrosis secondary to COVID-19: a call to arms?
|The Lancet Respiratory Medicine|2020|498
Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis: Test Validation and Minimal Clinically Important Difference
|American Journal of Respiratory and Critical Care Medicine|2010|457